RGEN SEC filings (2026)
CIK 730272 · Biological Products, (No Diagnostic Substances) (SIC 2836) · incorporated in DE · fiscal year ends in December
1,379 filings on EDGAR since 1995 · 34 annual, 100 quarterly, 252 current · financial statements · earnings
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
November 2026
October 2026
- Oct 30ReportQuarterly report, Q3 2026 — revenue $209.3M (+11% y/y), net income −$38.4M, EPS −$0.68
- Oct 308-K8-K · Re: Exchange and/or Subscription for Repligen Corporation 0.25% Convertible Senior Notes due 2031Unregistered sale of equity; Other events
- Oct 27EarningsEarnings release — EPS $0.53 vs $0.46 est. (+15.2%); revenue $209.3M (+11% y/y) 2.4%
- Oct 68-K8-K · REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONSCompletion of an acquisition or disposition; Regulation FD disclosure
- Oct 5Insider saleLoeillot Olivier (Chief Executive Officer · Director) sold 5,535 shares for $1.0M at $178.75–$190.00 under a 10b5-1 plan
September 2026
- Sep 24Insider saleLoeillot Olivier (Chief Executive Officer · Director) sold 12,946 shares for $2.5M at $190.00 under a 10b5-1 plan
- Sep 21Insider saleLoeillot Olivier (Chief Executive Officer · Director) sold 5,426 shares for $977K at $180.00 under a 10b5-1 plan
- Sep 158-K8-K · Directors or officers; compensation
- Sep 88-K8-K · Other events
- Sep 4Insider saleLoeillot Olivier (Chief Executive Officer · Director) sold 3,035 shares for $504K at $165.90 under a 10b5-1 plan
August 2026
July 2026
- Jul 29ReportQuarterly report, Q2 2026 — revenue $204.1M (+12% y/y), net income $5.0M, EPS $0.09
- Jul 28EarningsEarnings release — EPS $0.54 vs $0.45 est. (+20.0%); revenue $204.1M (+12% y/y) 10.9%
- Jul 228-K8-K · Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation MediaMaterial definitive agreement; Results of operations; Regulation FD disclosure; Other events
- Jul 16Insider saleGarland Jason K (CFO) sold 530 shares for $80K at $150.00 under a 10b5-1 plan
June 2026
May 2026
April 2026
- Apr 27ProxyProxy · Additional proxy materials
- Apr 21Insider saleLoeillot Olivier (Chief Executive Officer · Director) sold 3,832 shares for $536K at $140.00 under a 10b5-1 plan
- Apr 2ProxyProxy · Annual report to shareholders
- Apr 2ProxyProxy · Additional proxy materials
- Apr 2ProxyProxy · Proxy statement
February 2026
January 2026
- Jan 68-K8-K · REPLIGEN Executive chair tony hunt to retire; Dr. martin D. MadAus elected chairDirectors or officers; compensation; Regulation FD disclosure
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $6.7M in 8 sales and bought nothing on the open market; 58 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Oct 5, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorSold · $1.0M · 5,535 sh · 10b5-1 |
| Sep 24, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorSold · $2.5M · 12,946 sh · 10b5-1 |
| Sep 21, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorSold · $977K · 5,426 sh · 10b5-1 |
| Sep 4, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorSold · $504K · 3,035 sh · 10b5-1 |
| Aug 20, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorSold · $977K · 5,426 sh · 10b5-1 |
| Jul 16, 2026Form 4 | Garland Jason KCFOSold · $80K · 530 sh · 10b5-1 |
| Jun 25, 2026Form 4 | Garland Jason KCFOSold · $106K · 733 sh · 10b5-1 |
| Apr 21, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorSold · $536K · 3,832 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 58 transactions
| Date | Insider |
|---|---|
| Oct 6, 2026Form 4 | Douglass Brian RobbCHIEF PRODUCT OFFICERAward · $0 · 700 sh |
| Oct 6, 2026Form 4 | Douglass Brian RobbCHIEF PRODUCT OFFICERAward · Stock Option (Right to Buy) · $0 · 675 sh |
| Oct 5, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorExercise or conversion · $651K · 4,202 sh · 10b5-1 |
| Oct 5, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 4,202 sh · 10b5-1 |
| Oct 2, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorTax withholding · $227K · 1,248 sh |
| Sep 25, 2026Form 4 | Garland Jason KCFOTax withholding · $80K · 421 sh |
| Sep 24, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorExercise or conversion · $2.0M · 12,946 sh · 10b5-1 |
| Sep 24, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 12,946 sh · 10b5-1 |
| Sep 21, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorExercise or conversion · $769K · 5,426 sh · 10b5-1 |
| Sep 21, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 5,426 sh · 10b5-1 |
| Sep 3, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorTax withholding · $482K · 2,842 sh · 10b5-1 |
| Sep 1, 2026Form 4 | Hughes ViolettaCHIEF ACCOUNTING OFFICERTax withholding · $47K · 277 sh |
| Aug 20, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorExercise or conversion · $769K · 5,426 sh · 10b5-1 |
| Aug 20, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 5,426 sh · 10b5-1 |
| May 14, 2026Form 4 | BARTHELEMY NICOLASDirectorAward · Stock Option (Right to Buy) · $0 · 2,239 sh |
| May 14, 2026Form 4 | DAWES KAREN ADirectorAward · Stock Option (Right to Buy) · $0 · 2,239 sh |
| May 14, 2026Form 4 | Pax MargaretDirectorAward · Stock Option (Right to Buy) · $0 · 2,239 sh |
| May 14, 2026Form 4 | Mhatre RohinDirectorAward · Stock Option (Right to Buy) · $0 · 2,239 sh |
| May 14, 2026Form 4 | MUIR GLENN PDirectorAward · Stock Option (Right to Buy) · $0 · 2,239 sh |
| May 14, 2026Form 4 | EGLINTON MANNER CARRIEDirectorAward · Stock Option (Right to Buy) · $0 · 2,239 sh |
| May 14, 2026Form 4 | Madaus Martin DDirectorAward · Stock Option (Right to Buy) · $0 · 2,239 sh |
| May 14, 2026Form 4 | Konstantinov KonstantinDirectorAward · Stock Option (Right to Buy) · $0 · 2,239 sh |
| May 14, 2026Form 4 | BARTHELEMY NICOLASDirectorAward · $0 · 995 sh |
| May 14, 2026Form 4 | DAWES KAREN ADirectorAward · $0 · 995 sh |
| May 14, 2026Form 4 | Pax MargaretDirectorAward · $0 · 995 sh |
| May 14, 2026Form 4 | Mhatre RohinDirectorAward · $0 · 995 sh |
| May 14, 2026Form 4 | MUIR GLENN PDirectorAward · $0 · 995 sh |
| May 14, 2026Form 4 | EGLINTON MANNER CARRIEDirectorAward · $0 · 995 sh |
| May 14, 2026Form 4 | Madaus Martin DDirectorAward · $0 · 995 sh |
| May 14, 2026Form 4 | Konstantinov KonstantinDirectorAward · $0 · 995 sh |
| May 7, 2026Form 4 | MUIR GLENN PDirectorExercise or conversion · $94K · 2,434 sh |
| May 7, 2026Form 4 | Douglass Brian RobbCHIEF PRODUCT OFFICERTax withholding · $42K · 334 sh |
| May 7, 2026Form 4 | MUIR GLENN PDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 2,434 sh |
| Mar 5, 2026Form 4 | Loeillot OlivierChief Executive OfficerAward · Stock Option (Right to Buy) · $0 · 25,890 sh |
| Mar 5, 2026Form 4 | Loeillot OlivierChief Executive OfficerAward · $0 · 24,134 sh |
| Mar 5, 2026Form 4 | Garland Jason KCFOAward · Stock Option (Right to Buy) · $0 · 8,315 sh |
| Mar 5, 2026Form 4 | Bylund JamesChief Operating OfficerAward · Stock Option (Right to Buy) · $0 · 8,315 sh |
| Mar 5, 2026Form 4 | Garland Jason KCFOAward · $0 · 7,751 sh |
| Mar 5, 2026Form 4 | Bylund JamesChief Operating OfficerAward · $0 · 7,751 sh |
| Mar 5, 2026Form 4 | KURIYEL RALFSenior VP, R&DAward · Stock Option (Right to Buy) · $0 · 5,669 sh |
| Mar 5, 2026Form 4 | KURIYEL RALFSenior VP, R&DAward · $0 · 5,284 sh |
| Mar 5, 2026Form 4 | Hughes ViolettaCHIEF ACCOUNTING OFFICERAward · $0 · 2,466 sh |
| Mar 4, 2026Form 4 | Bylund JamesChief Operating OfficerTax withholding · $7,802 · 62 sh |
| Mar 4, 2026Form 4 | KURIYEL RALFSenior VP, R&DTax withholding · $5,285 · 42 sh |
| Mar 4, 2026Form 4 | KURIYEL RALFSenior VP, R&DAward · $0 · 125 sh |
| Mar 4, 2026Form 4 | Bylund JamesChief Operating OfficerAward · $0 · 125 sh |
| Mar 2, 2026Form 4 | Hunt AnthonyDirectorTax withholding · $1.2M · 9,897 sh |
| Mar 2, 2026Form 4 | Bylund JamesChief Operating OfficerTax withholding · $304K · 2,433 sh |
| Mar 2, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorTax withholding · $201K · 1,610 sh |
| Mar 2, 2026Form 4 | KURIYEL RALFSenior VP, R&DTax withholding · $115K · 923 sh |
| Mar 2, 2026Form 4 | Garland Jason KCFOTax withholding · $89K · 715 sh |
| Mar 2, 2026Form 4 | Douglass Brian RobbCHIEF PRODUCT OFFICERTax withholding · $28K · 221 sh |
| Feb 27, 2026Form 4 | Bylund JamesChief Operating OfficerTax withholding · $190K · 1,478 sh |
| Feb 27, 2026Form 4 | KURIYEL RALFSenior VP, R&DTax withholding · $57K · 444 sh |
| Feb 27, 2026Form 4 | Loeillot OlivierChief Executive Officer · DirectorTax withholding · $44K · 344 sh |
| Feb 27, 2026Form 4 | Garland Jason KCFOTax withholding · $42K · 327 sh |
| Dec 31, 2025Form 4 | Douglass Brian RobbCHIEF PRODUCT OFFICERAward · $0 · 2,288 sh |
| Dec 31, 2025Form 4 | Douglass Brian RobbCHIEF PRODUCT OFFICERAward · Stock Option (Right to Buy) · $0 · 2,143 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 20 filings
| Filed | What it is |
|---|---|
| Nov 6, 20268-K | Material definitive agreement; New financial obligation; Unregistered sale of equity |
| Oct 30, 202610-Q | Quarterly report, Q3 2026 — revenue $209.3M (+11% y/y), net income −$38.4M, EPS −$0.68 |
| Oct 30, 20268-K | Re: Exchange and/or Subscription for Repligen Corporation 0.25% Convertible Senior Notes due 2031Unregistered sale of equity; Other events |
| Oct 27, 20268-K | Earnings release — EPS $0.53 vs $0.46 est. (+15.2%); revenue $209.3M (+11% y/y) 2.4% |
| Oct 6, 20268-K | REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONSCompletion of an acquisition or disposition; Regulation FD disclosure |
| Sep 15, 20268-K | Directors or officers; compensation |
| Sep 8, 20268-K | Other events |
| Jul 29, 202610-Q | Quarterly report, Q2 2026 — revenue $204.1M (+12% y/y), net income $5.0M, EPS $0.09 |
| Jul 28, 20268-K | Earnings release — EPS $0.54 vs $0.45 est. (+20.0%); revenue $204.1M (+12% y/y) 10.9% |
| Jul 22, 20268-K | Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation MediaMaterial definitive agreement; Results of operations; Regulation FD disclosure; Other events |
| May 15, 20268-K | Shareholder vote results |
| May 6, 202610-Q | Quarterly report, Q1 2026 — revenue $194.3M (+15% y/y), net income $8.3M, EPS $0.15 |
| May 5, 20268-K | Earnings release — EPS $0.48 vs $0.38 est. (+26.3%); revenue $194.3M (+15% y/y) 6.3% |
| Apr 27, 2026DEFA14A | Additional proxy materials |
| Apr 2, 2026ARS | Annual report to shareholders |
| Apr 2, 2026DEFA14A | Additional proxy materials |
| Apr 2, 2026DEF 14A | Proxy statement |
| Feb 26, 202610-K | Annual report, FY2025 — revenue $738.3M (+16% y/y), net income $48.9M, EPS $0.86 |
| Feb 24, 20268-K | Earnings release — EPS $0.49 vs $0.44 est. (+11.4%); revenue $197.9M (+18% y/y) 0.5% |
| Jan 6, 20268-K | REPLIGEN Executive chair tony hunt to retire; Dr. martin D. MadAus elected chairDirectors or officers; compensation; Regulation FD disclosure |
2025 · 14 filings
| Filed | What it is |
|---|---|
| Nov 4, 202510-Q | Quarterly report, Q3 2025 — revenue $188.8M (+22% y/y), net income $14.9M, EPS $0.26 |
| Oct 28, 20258-K | Earnings release — EPS $0.46 vs $0.42 est. (+9.5%); revenue $188.8M (+22% y/y) 5.9% |
| Sep 2, 20258-K | Directors or officers; compensation |
| Aug 7, 202510-Q | Quarterly report, Q2 2025 — revenue $182.4M (+15% y/y), net income $14.9M, EPS $0.26 |
| Jul 29, 20258-K | Earnings release — EPS $0.37 vs $0.40 est. (−7.5%); revenue $182.4M (+15% y/y) 4.7% |
| May 15, 20258-K | Charter, bylaws or fiscal-year change; Shareholder vote results |
| Apr 29, 202510-Q | Quarterly report, Q1 2025 — revenue $169.2M (+10% y/y), net income $5.8M, EPS $0.10 |
| Apr 29, 20258-K | Earnings release — EPS $0.39 vs $0.35 est. (+11.4%); revenue $169.2M (+10% y/y) 2.9% |
| Apr 4, 2025ARS | Annual report to shareholders |
| Apr 4, 2025DEFA14A | Additional proxy materials |
| Apr 4, 2025DEF 14A | Proxy statement |
| Mar 17, 2025PRE 14A | Preliminary proxy statement |
| Mar 14, 202510-K | Annual report, FY2024 — revenue $634.4M (+0% y/y), net income −$25.5M, EPS −$0.46 |
| Feb 20, 20258-K | Earnings release — EPS $0.44 vs $0.41 est. (+7.3%); revenue $167.5M (+1% y/y) 7.9% |
2024 · 24 filings
| Filed | What it is |
|---|---|
| Nov 18, 202410-Q | Quarterly report, Q3 2024 — revenue $154.9M (+10% y/y), net income −$654K, EPS −$0.01 |
| Nov 18, 202410-Q/A | Quarterly report, amended |
| Nov 18, 202410-Q/A | Quarterly report, amended |
| Nov 18, 202410-K/A | Annual report, amended |
| Nov 18, 202410-Q/A | Quarterly report, amended |
| Nov 18, 202410-Q/A | Quarterly report, amended |
| Nov 18, 202410-Q/A | Quarterly report, amended |
| Nov 12, 20248-K | Earnings release — EPS $0.43 vs $0.34 est. (+26.5%); revenue $154.9M (+10% y/y) 6.5% |
| Sep 18, 20248-K | Results of operations; Non-reliance on prior financial statements; Regulation FD disclosure |
| Jul 30, 202410-Q | Quarterly report |
| Jul 30, 20248-K | Earnings release — EPS $0.33 vs $0.33 est. 16.4% |
| Jul 15, 20248-K | Other events |
| Jun 14, 20248-K | Directors or officers; compensation |
| Jun 13, 20248-K | Regulation FD disclosure |
| May 17, 20248-K | Shareholder vote results |
| May 3, 2024DEFA14A | Additional proxy materials |
| May 1, 202410-Q | Quarterly report |
| May 1, 20248-K | Earnings release — EPS $0.28 vs $0.29 est. (−3.5%) 3.6% |
| Apr 1, 2024ARS | Annual report to shareholders |
| Apr 1, 2024DEFA14A | Additional proxy materials |
| Apr 1, 2024DEF 14A | Proxy statement |
| Mar 19, 20248-K | Directors or officers; compensation; Regulation FD disclosure |
| Feb 22, 202410-K | Annual report |
| Feb 21, 20248-K | Earnings release — EPS $0.33 vs $0.34 est. (−2.9%) 2.8% |
2023 · 20 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Oct 31, 202310-Q | Quarterly report |
| Aug 2, 202310-Q | Quarterly report |
| May 2, 202310-Q | Quarterly report |
| Apr 11, 2023ARS | Annual report to shareholders |
| Apr 11, 2023DEF 14A | Proxy statement |
| Mar 24, 2023PRE 14A | Preliminary proxy statement |
| Feb 22, 202310-K | Annual report, FY2022 — revenue $801.5M (+20% y/y), net income $186.0M, EPS $3.24 |
13 current reports (8-K) not listed; the year is on EDGAR.
2022 · 13 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 1, 202210-Q | Quarterly report, Q3 2022 — revenue $200.7M (+13% y/y), net income $40.4M, EPS $0.71 |
| Aug 2, 202210-Q | Quarterly report, Q2 2022 — revenue $207.6M (+27% y/y), net income $49.9M, EPS $0.88 |
| Apr 27, 202210-Q | Quarterly report, Q1 2022 — revenue $206.4M (+45% y/y), net income $47.0M, EPS $0.81 |
| Apr 11, 2022DEFA14A | Additional proxy materials |
| Apr 11, 2022DEF 14A | Proxy statement |
| Feb 17, 202210-K | Annual report, FY2021 — revenue $670.5M (+83% y/y), net income $128.3M, EPS $2.24 |
7 current reports (8-K) not listed; the year is on EDGAR.
2021 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 28, 202110-Q | Quarterly report, Q3 2021 — revenue $178.2M (+89% y/y), net income $33.5M, EPS $0.58 |
| Jul 27, 202110-Q | Quarterly report, Q2 2021 — revenue $163.0M (+86% y/y), net income $36.2M, EPS $0.64 |
| May 5, 2021DEFR14A | Proxy statements |
| May 4, 202110-Q | Quarterly report, Q1 2021 — revenue $142.8M (+88% y/y), net income $29.4M, EPS $0.52 |
| Apr 21, 2021DEF 14A | Proxy statement |
| Feb 24, 202110-K | Annual report, FY2020 — revenue $366.3M (+36% y/y), net income $59.9M, EPS $1.11 |
9 current reports (8-K) not listed; the year is on EDGAR.
2020 · 16 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
| Filed | What it is |
|---|---|
| Nov 5, 202010-Q | Quarterly report, Q3 2020 — revenue $94.1M (+35% y/y), net income $14.6M, EPS $0.27 |
| Jul 30, 202010-Q | Quarterly report, Q2 2020 — revenue $87.5M (+24% y/y), net income $15.9M, EPS $0.30 |
| May 6, 202010-Q | Quarterly report, Q1 2020 — revenue $76.1M (+25% y/y), net income $9.8M, EPS $0.18 |
| Apr 28, 2020DEF 14A | Proxy statement |
| Feb 26, 202010-K | Annual report, FY2019 — revenue $270.2M (+39% y/y), net income $21.4M, EPS $0.44 |
11 current reports (8-K) not listed; the year is on EDGAR.
2019 · 19 filings — 12 × 8-K, 3 × 10-Q, 2 × 8-K/A and 2 other forms
| Filed | What it is |
|---|---|
| Oct 31, 201910-Q | Quarterly report, Q3 2019 — revenue $69.4M (+40% y/y), net income $1.7M, EPS $0.03 |
| Aug 1, 201910-Q | Quarterly report, Q2 2019 — revenue $70.7M (+48% y/y), net income $8.1M, EPS $0.17 |
| May 9, 201910-Q | Quarterly report, Q1 2019 — revenue $60.6M (+35% y/y), net income $8.1M, EPS $0.17 |
| Apr 18, 2019DEF 14A | Proxy statement |
| Mar 1, 201910-K | Annual report, FY2018 — revenue $194.0M (+37% y/y), net income $16.6M, EPS $0.37 |
14 current reports (8-K) not listed; the year is on EDGAR.
2018 · 12 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 1, 201810-Q | Quarterly report, Q3 2018 — revenue $49.5M (+35% y/y), net income $4.8M, EPS $0.10 |
| Aug 2, 201810-Q | Quarterly report, Q2 2018 — revenue $47.7M (+47% y/y), net income $2.7M, EPS $0.06 |
| May 8, 201810-Q | Quarterly report, Q1 2018 — revenue $44.8M (+47% y/y), net income $3.4M, EPS $0.08 |
| May 3, 2018DEFA14A | Additional proxy materials |
| Apr 20, 2018DEF 14A | Proxy statement |
| Feb 22, 201810-K | Annual report, FY2017 — revenue $141.2M (+35% y/y), net income $28.4M, EPS $0.72 |
6 current reports (8-K) not listed; the year is on EDGAR.
2017 · 18 filings — 9 × 8-K, 3 × 10-Q, 3 × 8-K/A and 3 other forms
| Filed | What it is |
|---|---|
| Nov 9, 201710-Q | Quarterly report, Q3 2017 — revenue $36.6M (+48% y/y), net income $4.7M, EPS $0.11 |
| Aug 3, 201710-Q | Quarterly report, Q2 2017 — revenue $32.5M (+11% y/y), net income $8.4M, EPS $0.24 |
| May 4, 201710-Q | Quarterly report, Q1 2017 — revenue $30.6M (+22% y/y), net income $3.1M, EPS $0.09 |
| Apr 21, 2017DEF 14A | Proxy statement |
| Apr 7, 2017PRE 14A | Preliminary proxy statement |
| Feb 23, 201710-K | Annual report, FY2016 — revenue $104.5M (+25% y/y), net income $11.7M, EPS $0.34 |
12 current reports (8-K) not listed; the year is on EDGAR.
2016 · 17 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2015 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2014 · 19 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
Counted, not listed; the year is on EDGAR.
2013 · 14 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2012 · 21 filings — 14 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2011 · 20 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2010 · 12 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2009 · 10 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2008 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2007 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2006 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2005 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2004 · 14 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2003 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2002 · 14 filings — 6 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
Counted, not listed; the year is on EDGAR.
2001 · 5 filings — 3 × 10-Q, 1 × 10-K, 1 × DEF 14A
Counted, not listed; the year is on EDGAR.
2000 · 7 filings — 3 × 10-Q, 2 × 8-K, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
1999 · 10 filings — 3 × 10-Q, 3 × 8-K, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
1998 · 6 filings — 3 × 10-Q, 1 × 10-K, 1 × 8-K and 1 other form
Counted, not listed; the year is on EDGAR.
1997 · 5 filings — 3 × 10-Q, 1 × 10-K, 1 × DEF 14A
Counted, not listed; the year is on EDGAR.
1996 · 5 filings — 3 × 10-Q, 1 × 10-K, 1 × DEF 14A
Counted, not listed; the year is on EDGAR.
1995 · 5 filings — 2 × 10-Q, 1 × 10-K, 1 × 10-K/A and 1 other form
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 62 filings — 35 × 4, 9 × 144, 6 × 425 and 7 other forms
| Filed | What it is |
|---|---|
| Oct 8, 20264 | Insider transaction (Form 4) |
| Oct 7, 2026SCHEDULE 13G/A | Other filings |
| Oct 6, 20264 | Insider transaction (Form 4) |
| Oct 5, 2026144 | Notice of proposed sale (Form 144) |
| Oct 5, 20264 | Insider transaction (Form 4) |
| Oct 5, 2026144 | Notice of proposed sale (Form 144) |
| Sep 30, 2026425 | Merger communication |
| Sep 28, 20264 | Insider transaction (Form 4) |
| Sep 25, 20264 | Insider transaction (Form 4) |
| Sep 24, 2026144 | Notice of proposed sale (Form 144) |
| Sep 22, 20264 | Insider transaction (Form 4) |
| Sep 21, 2026144 | Notice of proposed sale (Form 144) |
| Sep 8, 2026425 | Merger communication |
| Sep 8, 20264 | Insider transaction (Form 4) |
| Sep 4, 2026EFFECT | Other filings |
| Sep 4, 2026424B3 | Prospectus |
| Sep 4, 2026144 | Notice of proposed sale (Form 144) |
| Sep 4, 2026S-4/A | Merger or exchange registration, amended |
| Sep 2, 20264 | Insider transaction (Form 4) |
| Aug 25, 2026S-4 | Merger or exchange registration |
| Aug 21, 20264 | Insider transaction (Form 4) |
| Aug 20, 2026144 | Notice of proposed sale (Form 144) |
| Aug 14, 2026SCHEDULE 13G/A | Other filings |
| Aug 4, 2026425 | Merger communication |
| Jul 31, 2026SCHEDULE 13G | Other filings |
The newest 25 of 62 shown; the full year is on EDGAR.
2025 · 56 filings — 39 × 4, 8 × 144, 4 × SCHEDULE 13G/A and 4 other forms
| Filed | What it is |
|---|---|
| Dec 18, 20254 | Insider transaction (Form 4) |
| Dec 17, 20254 | Insider transaction (Form 4) |
| Dec 17, 2025144 | Notice of proposed sale (Form 144) |
| Dec 8, 20254 | Insider transaction (Form 4) |
| Nov 26, 20254 | Insider transaction (Form 4) |
| Nov 25, 2025144 | Notice of proposed sale (Form 144) |
| Nov 19, 20254 | Insider transaction (Form 4) |
| Nov 18, 2025144 | Notice of proposed sale (Form 144) |
| Nov 14, 20254 | Insider transaction (Form 4) |
| Nov 13, 20254 | Insider transaction (Form 4) |
| Nov 13, 2025144 | Notice of proposed sale (Form 144) |
| Nov 12, 2025144 | Notice of proposed sale (Form 144) |
| Oct 6, 20254 | Insider transaction (Form 4) |
| Sep 26, 20254 | Insider transaction (Form 4) |
| Sep 11, 20254 | Insider transaction (Form 4) |
| Sep 10, 2025144 | Notice of proposed sale (Form 144) |
| Sep 10, 2025UPLOAD | Letter from the SEC staff |
| Sep 8, 2025SCHEDULE 13G/A | Other filings |
| Sep 4, 20254 | Insider transaction (Form 4) |
| Sep 4, 20254 | Insider transaction (Form 4) |
| Sep 4, 20253 | Initial insider holdings (Form 3) |
| Aug 26, 2025CORRESP | Letter to the SEC |
| Aug 14, 2025UPLOAD | Letter from the SEC staff |
| Aug 12, 20254 | Insider transaction (Form 4) |
| May 21, 20254 | Insider transaction (Form 4) |
The newest 25 of 56 shown; the full year is on EDGAR.
2024 · 75 filings — 51 × 4, 10 × 144, 8 × SC 13G/A and 5 other forms
| Filed | What it is |
|---|---|
| Dec 5, 20244 | Insider transaction (Form 4) |
| Nov 22, 20244 | Insider transaction (Form 4) |
| Nov 21, 2024144 | Notice of proposed sale (Form 144) |
| Nov 21, 20244 | Insider transaction (Form 4) |
| Nov 21, 20244 | Insider transaction (Form 4) |
| Nov 20, 20244 | Insider transaction (Form 4) |
| Nov 14, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 12, 2024NT 10-Q | Late-filing notice (10-Q) |
| Nov 12, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Oct 23, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Sep 12, 20244 | Insider transaction (Form 4) |
| Sep 10, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Sep 10, 2024144 | Notice of proposed sale (Form 144) |
| Sep 4, 20244 | Insider transaction (Form 4) |
| Sep 4, 20244 | Insider transaction (Form 4) |
| Aug 19, 20244/A | Insider transaction (Form 4), amended |
| Aug 12, 2024UPLOAD | Letter from the SEC staff |
| Aug 6, 2024CORRESP | Letter to the SEC |
| Aug 5, 20244 | Insider transaction (Form 4) |
| Aug 2, 2024144 | Notice of proposed sale (Form 144) |
| Aug 1, 20244 | Insider transaction (Form 4) |
| Aug 1, 20244 | Insider transaction (Form 4) |
| Aug 1, 2024144 | Notice of proposed sale (Form 144) |
| Aug 1, 2024144 | Notice of proposed sale (Form 144) |
| Jul 24, 2024UPLOAD | Letter from the SEC staff |
The newest 25 of 75 shown; the full year is on EDGAR.
2023 · 44 filings — 33 × 4, 4 × SC 13G/A, 3 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2022 · 44 filings — 38 × 4, 2 × SC 13G, 2 × SC 13G/A and 2 other forms
Counted, not listed; the year is on EDGAR.
2021 · 50 filings — 42 × 4, 3 × SC 13G/A, 2 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2020 · 50 filings — 41 × 4, 3 × SC 13G/A, 2 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2019 · 41 filings — 23 × 4, 6 × 424B5, 4 × 4/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2018 · 43 filings — 33 × 4, 3 × SC 13G/A, 2 × SC 13G and 5 other forms
Counted, not listed; the year is on EDGAR.
2017 · 38 filings — 18 × 4, 5 × 4/A, 4 × SC 13G/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2016 · 32 filings — 20 × 4, 3 × SC 13G/A, 2 × 424B5 and 6 other forms
Counted, not listed; the year is on EDGAR.
2015 · 38 filings — 27 × 4, 2 × CORRESP, 2 × SC 13G and 5 other forms
Counted, not listed; the year is on EDGAR.
2014 · 43 filings — 30 × 4, 3 × 3, 2 × 4/A and 6 other forms
Counted, not listed; the year is on EDGAR.
2013 · 34 filings — 24 × 4, 3 × SC 13G/A, 2 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2012 · 33 filings — 15 × 4, 7 × SC 13D/A, 4 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2011 · 19 filings — 13 × 4, 3 × SC 13D/A, 2 × SC 13G/A and 1 other form
Counted, not listed; the year is on EDGAR.
2010 · 20 filings — 14 × 4, 3 × SC 13G/A, 2 × CT ORDER and 1 other form
Counted, not listed; the year is on EDGAR.
2009 · 27 filings — 8 × 4, 4 × CORRESP, 4 × UPLOAD and 5 other forms
Counted, not listed; the year is on EDGAR.
2008 · 12 filings — 7 × 4, 2 × 3, 2 × SC 13G/A and 1 other form
Counted, not listed; the year is on EDGAR.
2007 · 30 filings — 19 × 4, 2 × 4/A, 2 × CORRESP and 5 other forms
Counted, not listed; the year is on EDGAR.
2006 · 29 filings — 20 × 4, 3 × 4/A, 3 × SC 13G/A and 2 other forms
Counted, not listed; the year is on EDGAR.
2005 · 25 filings — 20 × 4, 1 × 3, 1 × 5 and 3 other forms
Counted, not listed; the year is on EDGAR.
2004 · 17 filings — 14 × 4, 1 × 3, 1 × 5 and 1 other form
Counted, not listed; the year is on EDGAR.
2003 · 16 filings — 8 × 4, 4 × SC 13G/A, 1 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2002 · 7 filings — 3 × 4, 3 × SC 13G/A, 1 × S-8
Counted, not listed; the year is on EDGAR.
2001 · 8 filings — 4 × SC 13G/A, 3 × 4, 1 × SC 13G
Counted, not listed; the year is on EDGAR.
2000 · 14 filings — 5 × 4, 4 × S-3, 2 × S-3/A and 2 other forms
Counted, not listed; the year is on EDGAR.
1999 · 10 filings — 3 × S-3/A, 2 × S-3, 2 × SC 13G/A and 3 other forms
Counted, not listed; the year is on EDGAR.
1998 · 6 filings — 2 × SC 13D, 2 × SC 13G, 1 × S-3 and 1 other form
Counted, not listed; the year is on EDGAR.
1997 · 11 filings — 7 × SC 13D/A, 2 × 4, 1 × 424B3 and 1 other form
Counted, not listed; the year is on EDGAR.
1996 · 2 filings — 1 × NT 10-Q, 1 × SC 13D
Counted, not listed; the year is on EDGAR.
1995 · 1 filing — 1 × NT 10-K
Counted, not listed; the year is on EDGAR.
About this data#
Repligen Corporation (RGEN) has 1,379 filings on EDGAR going back to 1995: 34 annual reports, 100 quarterly reports and 252 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 26, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Nov 6, 2026, covered material definitive agreement; new financial obligation; unregistered sale of equity. Over the last 13 months insiders sold $6.7M in 8 sales and bought nothing on the open market; 58 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Repligen Corporation, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read RGEN's latest 10-K?
- RGEN's latest annual report, a 10-K, was filed on Feb 26, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did RGEN last file an 8-K?
- On Nov 6, 2026 it covered material definitive agreement; new financial obligation; unregistered sale of equity. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Oct 27, 2026.
- Are RGEN insiders buying or selling?
- Over the last 13 months insiders sold $6.7M in 8 sales and bought nothing on the open market; 58 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Loeillot Olivier (Chief Executive Officer · Director) sold 5,535 shares on Oct 5, 2026 for $1.0M, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has RGEN made?
- 1,379 filings are on EDGAR under the registrant records that have been Repligen Corporation, going back to 1995; 698 of them are insider ownership forms (Forms 3, 4, 5 and 144).